Breast Cancer

Data from the T-DXd monotherapy arm of the phase 3 DESTINY-Breast09 trial will remain blinded until the final PFS analysis.

Sacituzumab govitecan plus pembrolizumab showed a trend for improved overall survival vs standard of care in patients with untreated PD-L1–positive TNBC.

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

No treatment-related discontinuations have been observed related to Bria-IMT treatment for hormone receptor–positive breast cancer.

Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.

Neil M. Iyengar, MD, discussed the most prevalent discussions and exciting updates from the 2025 Miami Breast Cancer Conference.

Race, education, and arm pain were found to influence acupuncture expectancy in patients who are survivors of breast cancer.

Identifying biologic mechanisms driving symptoms may be necessary to develop therapies that reduce symptom burden for patients with breast cancer.

The developer will conduct a US feasibility test to evaluate the safety and efficacy of the SIRA RFA Electrosurgical Device in patients who require breast-conservation surgery.

Palbociclib with endocrine therapy did not improve outcomes in hormone receptor–positive, HER2-negative breast cancer but improved invasive DFS in lobular disease.

Results from the phase 3 DESTINY-Breast06 trial demonstrated that trastuzumab deruxtecan (T-DXd) monotherapy improved progression-free survival over chemotherapy in patients with breast cancer.

“We see that those taking chemotherapy are going to be the ones that are going to require the most help,” Clara Bodelon, PhD, MS, said regarding breast cancer treatment.

At 5 years, 100% of patients with breast cancer who did not receive surgery had ipsilateral breast tumor relapse-free survival.

Patients with breast cancer who were treated with chemotherapy may have more pain, fatigue, and difficulty moving vs those who received endocrine therapy or did not have breast cancer.

Clara Bodelon, PhD, MS, discussed her recently published study which found that the greatest physical health declines in patients who survived breast cancer stemmed from chemotherapy.